We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 07, 2022

TET2 Inhibits VHL-Deficient ccRCC by Targeting HIF Signaling

Cancer Research


Additional Info

Cancer Research
TET2 suppresses VHL deficiency-driven clear cell renal cell carcinoma by inhibiting HIF signaling
Cancer Res 2022 Feb 17;[EPub Ahead of Print], X Zhang, S Li, J He, YJ Jin, R Zhang, W Dong, M Lin, Y Yang, T Tian, Y Zhou, Y Xu, QY Lei, J Zhang, Q Zhang, Y Xu, L Lv

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading